Resources

In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.

In this blog, Tom Sheldon, Senior Manager at the Science Media Centre (SMC), explores how scientists and communicators are taking on misinformation head-on — and how the SMC’s work supports both researchers and journalists in helping the public make sense of complex, and sometimes controversial, scientific issues.

A London-based biotech firm that aims to improve infant health with its research into the microbiomes of breast milk has raised £2.5 million.

Logical Biological, biospecimen and critical raw material leader based at Discovery Park, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic international partnership to deliver engineered disease state materials for diagnostic and research markets.

Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.

Pioneer Group has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.

Research conducted by Pioneer Group in collaboration with Beauhurst into the UK life sciences landscape reveals a growing trend of investment into more mature companies.

Construction of Europe’s tallest and most technically sophisticated purpose-built commercial lab building has started on site at Canary Wharf, London.

Tailor Bio announced the publication of a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types.

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.

Positive news ahead of Spending Review (join our webinar this Friday), latest on getting pensions investment into UK life sciences and more!

Pension capital is unlocked in time for BIA's Parliament Day this Wednesday.

We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar. 

Since joining the TechBio Boost programme, SokerData has refined its business model, adopted a more strategic approach to market entry, built new partnerships and is securing funding to accelerate R&D and commercialisation.

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at BIA, explores a major milestone for agricultural innovation in England: the implementation of a clear, science-based regulatory pathway for precision-bred plants.